Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001958244-24-003921
Filing Date
2024-08-13
Accepted
2024-08-13 17:20:23
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 4129
  Complete submission text file 0001958244-24-003921.txt   5966
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Subject) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 144 | Act: 33 | File No.: 001-36410 | Film No.: 241203016
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 300 FRANK W. BURR BLVD., STE 21 TEANECK NJ 07666
Business Address 300 FRANK W. BURR BLVD., STE 21 TEANECK NJ 07666 2013297300
BFI Co., LLC (Reporting) CIK: 0001601607 (see all company filings)

EIN.: 262105186 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144